The organization of the transcriptional network in specific neuronal classes

Genome-wide expression profiling has aided the understanding of the molecular basis of neuronal diversity, but achieving broad functional insight remains a considerable challenge. Here, we perform the first systems-level analysis of microarray data from single neuronal populations using weighted gene co-expression network analysis to examine how neuronal transcriptome organization relates to neuronal function and diversity. We systematically validate network predictions using published proteomic and genomic data. Several network modules of co-expressed genes correspond to interneuron development programs, in which the hub genes are known to be critical for interneuron specification. Other co-expression modules relate to fundamental cellular functions, such as energy production, firing rate, trafficking, and synapses, suggesting that fundamental aspects of neuronal diversity are produced by quantitative variation in basic metabolic processes. We identify two transcriptionally distinct mitochondrial modules and demonstrate that one corresponds to mitochondria enriched in neuronal processes and synapses, whereas the other represents a population restricted to the soma. Finally, we show that galectin-1 is a new interneuron marker, and we validate network predictions in vivo using Rgs4 and Dlx1/2 knockout mice. These analyses provide a basis for understanding how specific aspects of neuronal phenotypic diversity are organized at the transcriptional level

THE DISPERSION OF AGRICULTURAL AND RURAL DEVELOPMENT EU FUNDS ON A REGIONAL AND DISTRICT LEVEL IN HUNGARY

A national objective was realised when Hungary joined the European Union based on the preliminary result of the referendum. Naturally, there were pros and cons about the accession and there were those who refused the European integration. Still the emotion was stronger that came from the future EU membership and the hope in terms of the agriculture that with the opportunities offered by the EU both the Hungarian agriculture and countryside would follow a development course. Because of the accession a lot of support forms as well as the EU institutions became available but considering the impacts there were no clear positions. Obviously, today we know what kind of objective, positive changes were brought by the accession for example in terms of infrastructural and machine supply, broadened market possibilities and income growth. Still we also experience the objective disadvantages such as the stronger competition and the mass expansion of multinational food-processing and trading companies. The scientific measurement and judgement of the developmental changes which are difficult to measure is still a subject of debate. We have done the concentration analysis for two budget periods 2004-2006 and 2007-2013 respectively. Between 2004-2006 the regional concentration is more balanced year by year than the district. In the district values even in this period we can already experience the fact that very few farmers receive a big amount of support. Between 2007-2013 there are no sharp differences in the case of concentration neither in the region nor in the district. The Lorenz curve shows a classic concentration distribution in the Southern Great Plain Region every year. The course of Lorenz curves is supported by the value of the concentration ratio which is the total share of the support of the three players receiving the biggest funds since the indicator has been hovering around the 10% average value in the region since 2006 while in the district we can experience values within a 36% and 17% average intervals. By evaluating the funds data of the Southern Great Plain Region and Sarkad district we can state that by 2013 the concentration has balanced out in both areas still we can experience a significant funds-concentration on the district level

Serum thyroglobulin antibody levels within or near to the reference range may interfere with thyroglobulin measurement

High concentration of thyroglobulin antibodies (TgAb) is a major limiting factor of thyroglobulin measurements in patients with differentiated thyroid cancer. We investigated whether thyroglobulin antibody added to serum samples could interfere with the thyroglobulin assay. Thyroglobulin levels in serum samples with different concentrations of thyroglobulin were measured by electrochemiluminescence immunoassay before and after the addition of increasing concentrations of thyroglobulin antibody using the secondary calibrator solution of the thyroglobulin assay kit containing sheep thyroglobulin antibody to reach thyroglobulin antibody levels within or near to the reference range. Thyroglobulin and thyroglobulin antibody concentrations were also measured in 134 serum samples from 27 patients after thyroid ablation. There was a strong negative association (slope = -1.179) between thyroglobulin antibody and thyroglobulin concentrations in samples with added thyroglobulin antibody (beta = -0.86; P < 0.001). Changes in thyroglobulin concentrations were described mathematically as loss of thyroglobulin% = -0.2408 x Ln(thyroglobulin antibody IU/ml) + 0.1944. Thyroglobulin concentrations were significantly lower than those calculated from experiments with added thyroglobulin antibody in 26/134 samples from patients after thyroid ablation. We conclude that if the same TgAb interference exists in the presence of naturally occurring human TgAb, our observation may prove to be useful during follow-up of patients with differentiated thyroid cancer. However, further studies are needed to explore the clinical relevance of thyroglobulin antibody levels within or near to the reference range in monitoring these patients

A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers

Epidermal growth factor (EGF) and its receptors (EGFR) play important roles in tumorigenesis. In various experimental cancers, treatment with antagonists of bombesin/gastrin-releasing peptide (BN/GRP) produces a reduction in EGFRs, concomitant to inhibition of tumor growth. To investigate the mechanisms involved, we monitored concentrations of BN/GRP antagonist RC-3095 in serum of mice, rats, and hamsters given a single subcutaneous or intravenous injection of this analog. In parallel studies, we measured levels and mRNA expression of EGFRs in estrogen-dependent and independent MXT mouse mammary cancers, following a single subcutaneous administration of RC-3095 to tumor-bearing mice. Peak values of RC-3095 in serum were detected 2 min after intravenous or 15 min after subcutaneous injection. The levels of RC-3095 declined rapidly and became undetectable after 3–5 hr. In the estrogen-dependent MXT tumors, the concentration of EGF receptors was reduced by about 60% 6 hr following injection and returned to original level after 24 hr. Levels of mRNA for EGFR fell parallel with the receptor number and were nearly normal after 24 hr. In the hormone-independent MXT cancers, the number of EGFRs decreased progressively, becoming undetectable 6 hr after injection of RC-3095, and returned to normal values at 24 hr, but EGFR mRNA levels remained lower for 48 hr. Thus, in spite of rapid elimination from serum, BN/GRP antagonist RC-3095 can induce a prolonged decrease in levels and mRNA expression of EGFRs. These findings may explain how single daily injections of BN/GRP antagonists can maintain tumor growth inhibition